Mikhail Kosiborod, MD
Cardiovascular Disease · Kansas City, MONPI 1588613657
Payments from drug & device makers
Across 1,260 payments — averaging $22,030 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23.3M
- Boehringer Ingelheim$2.2M
- Bayer$848K
- Novo Nordisk AS$451K
- Novo Nordisk$248K
- Pfizer$203K
- plus $564K from 24 others
Across 13 payments — averaging $3213.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$13K
- Novo Nordisk AS$10K
- Amgen$9K
- Boehringer Ingelheim International GmbH$5K
- Pfizer$4K
- Novo Nordisk$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $23,276,659 |
| Boehringer Ingelheim | 25 | $2,167,089 |
| Bayer | 90 | $847,756 |
| Novo Nordisk AS | 650 | $450,689 |
| Novo Nordisk | 87 | $248,409 |
| Pfizer | 7 | $203,010 |
| Amgen | 52 | $157,306 |
| Astrazeneca UK Limited | 77 | $100,852 |
| Boehringer Ingelheim International GmbH | 62 | $86,987 |
| Eli Lilly | 49 | $61,541 |
| Sanofi-aventis U.S. LLC | 15 | $51,345 |
| Vifor (international) Ltd. | 4 | $20,289 |
| Janssen Scientific Affairs, LLC | 10 | $18,746 |
| Merck | 8 | $15,748 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $11,486 |
| Sanofi US Services Inc. | 2 | $7,257 |
| Astrazeneca AB | 8 | $6,506 |
| Corcept Therapeutics | 6 | $6,182 |
| Amarin Pharma, Inc. | 8 | $5,482 |
| Esperion Therapeutics, Inc. | 6 | $2,884 |
| F. Hoffmann-la Roche AG | 2 | $2,573 |
| Lilly USA, LLC | 1 | $2,400 |
| Boehringer Ingelheim India Pvt. Ltd. | 1 | $1,775 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,500 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,230 |
| Regeneron | 2 | $1,007 |
| Dexcom, Inc. | 1 | $650 |
| Novartis | 2 | $231 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Gilead | 2 | $167 |
How this compares
$27,757,944 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Kansas City
- John SpertusKansas City$2.3M
- Rajat BaruaKansas City$264K
- Kyle LehenbauerKansas City$108K
- Paramdeep BawejaKansas City$68K
- Deepa UpadhyayaKansas City$58K
- John LeeKansas City$45K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Mohammad TahirSaint Louis$2.7M
- Joshua MitchellSaint Louis$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.